

## SUPPLEMENTARY TABLES

**Supplementary Table 1.** The correlation of FXYD1 expression with clinicopathologic characteristics of CC patients.

Variable	Cases (n)		High 129	Low 326	<i>P</i> value
	455				
Age	≥60	332	91	241	0.483
	<60	123	38	85	
Gender	Male	241	67	174	0.835
	Female	214	62	152	
T stage	T1/T2	88	18	70	0.086
	T3/T4	367	111	256	
N stage	Negative	267	59	208	<0.001*
	Positive	188	70	118	
M stage	Negative	339	89	250	0.096
	Positive	116	40	76	

\*, *P*<0.05.

**Supplementary Table 2.** The correlation of FXYD2 expression with clinicopathologic characteristics of CC patients.

Variable	Cases (n)		High 409	Low 46	<i>P</i> value
	455				
Age	≥60	332	296	36	0.485
	<60	123	113	10	
Gender	Male	241	212	29	0.163
	Female	214	197	17	
T stage	T1/T2	88	71	17	0.003*
	T3/T4	367	338	29	
N stage	Negative	267	236	31	0.269
	Positive	188	173	15	
M stage	Negative	339	303	36	0.597
	Positive	116	106	10	

\*, *P*<0.05.

**Supplementary Table 3. The correlation of FXYD3 expression with clinicopathologic characteristics of CC patients.**

<b>Variable</b>	<b>Cases (n)</b>		<b>High</b> <b>323</b>	<b>Low</b> <b>132</b>	<b>P value</b>
	<b>455</b>				
Age	≥60	332	235	97	0.908
	<60	123	88	35	
Gender	Male	241	169	72	0.680
	Female	214	154	60	
T stage	T1/T2	88	66	22	0.433
	T3/T4	367	257	110	
N stage	Negative	267	201	66	0.021*
	Positive	188	122	66	
M stage	Negative	339	250	89	0.033*
	Positive	116	73	43	

\*, P<0.05.

**Supplementary Table 4. The correlation of FXYD4 expression with clinicopathologic characteristics of CC patients.**

<b>Variable</b>	<b>Cases (n)</b>		<b>High</b> <b>153</b>	<b>Low</b> <b>302</b>	<b>P value</b>
	<b>455</b>				
Age	≥60	332	114	218	0.655
	<60	123	39	84	
Gender	Male	241	93	148	0.022*
	Female	214	60	154	
T stage	T1/T2	88	29	59	1.000
	T3/T4	367	124	243	
N stage	Negative	267	90	177	1.000
	Positive	188	63	125	
M stage	Negative	339	113	226	0.821
	Positive	116	40	76	

\*, P<0.05.

**Supplementary Table 5. The correlation of FXYD5 expression with clinicopathologic characteristics of CC patients.**

Variable	Cases (n)		High 171	Low 284	<i>P</i> value
	455				
Age	≥60	332	132	200	0.128
	<60	123	39	84	
Gender	Male	241	93	148	0.698
	Female	214	78	136	
T stage	T1/T2	88	24	64	0.028*
	T3/T4	367	147	220	
N stage	Negative	267	92	175	0.116
	Positive	188	79	109	
M stage	Negative	339	124	215	0.505
	Positive	116	47	69	

\*, *P*<0.05.

**Supplementary Table 6. The correlation of FXYD6 expression with clinicopathologic characteristics of CC patients.**

Variable	Cases (n)		High 183	Low 272	<i>P</i> value
	455				
Age	≥60	332	123	209	0.031*
	<60	123	60	63	
Gender	Male	241	93	148	0.503
	Female	214	90	124	
T stage	T1/T2	88	28	60	0.090
	T3/T4	367	155	212	
N stage	Negative	267	90	177	0.001*
	Positive	188	93	95	
M stage	Negative	339	131	208	0.273
	Positive	116	52	64	

\*, *P*<0.05.

**Supplementary Table 7. The correlation of FXYD7 expression with clinicopathologic characteristics of CC patients.**

Variable	Cases (n)	High	Low	P value
		455	158	
Age	≥60	332	113	0.658
	<60	123	45	
Gender	Male	241	92	0.115
	Female	214	66	
T stage	T1/T2	88	29	0.803
	T3/T4	367	129	
N stage	Negative	267	84	0.090
	Positive	188	74	
M stage	Negative	339	117	0.910
	Positive	116	41	